Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design

被引：41

作者：

Jones, Spencer B. ^{[1
]}

Pfeifer, Lance A. ^{[1
]}

Bleisch, Thomas J. ^{[1
]}

Beauchamp, Thomas J. ^{[1
]}

Durbin, Jim D. ^{[1
]}

Klimkowski, V. Joseph ^{[1
]}

Hughes, Norman E. ^{[1
]}

Rito, Christopher J. ^{[1
]}

Dao, Yen ^{[1
]}

Gruber, Joseph M. ^{[1
,2
]}

Bui, Hai ^{[1
]}

Chambers, Mark G. ^{[1
]}

Chandrasekhar, Srinivasan ^{[1
]}

Lin, Chaohua ^{[1
]}

McCann, Denis J. ^{[1
]}

Mudra, Daniel R. ^{[1
]}

Oskins, Jennifer L. ^{[1
]}

Swearingen, Craig A. ^{[1
]}

Thirunavukkarasu, Kannan ^{[1
]}

Norman, Bryan H. ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA

[2] Dow AgroSci, Zionsville, IN 46268 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2016年 / 7卷 / 09期

关键词：

Autotaxin; tool molecule; osteoarthritis; LPA; LYSOPHOSPHATIDIC ACID PRODUCTION; ARTHRITIS; MOTILITY; SITE; LPA;

D O I：

10.1021/acsmedchemlett.6b00207

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In an effort to develop a novel therapeutic agent aimed at addressing the unmet need of patients with osteoarthritis pain, we set out to develop an inhibitor for autotaxin with excellent potency and physical properties to allow for the clinical investigation of autotaxin-induced nociceptive and neuropathic pain. An initial hit identification campaign led to an aminopyrimidine series with an autotaxin IC50 of 500 nM. X-ray crystallography enabled the optimization to a lead compound that demonstrated favorable potency (IC50 = 2 nM), PK properties, and a robust PK/PD relationship.

引用

页码：857 / 861

页数：5

共 50 条

[31] Structure-based drug design of HIV protease inhibitors.
Navia, MA
Tung, RD
Chaturvedi, PR
Rao, BG
Partaledis, JA
Kim, EE
FASEB JOURNAL, 1996, 10 (06): : 2436 - 2436
[32] Structure-based drug design of TRAF6 inhibitors
Peng, Zhenghong
Maxwell, David S.
Sun, Duoli
Darnay, Bryant G.
Bornmann, William G.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
[33] STRUCTURE-BASED DRUG DESIGN - INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE
MONTGOMERY, JA
EALICK, SE
BABU, S
BUGG, CE
ERION, MD
GUIDA, WC
SECRIST, JA
JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 206 - 206
[34] STRUCTURE-BASED DRUG DESIGN - INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE
MONTGOMERY, JA
FARMACO, 1993, 48 (02): : 297 - 308
[35] Structure-based drug design of selective 5′-nucleotidases inhibitors
Pachl, P.
Brynda, J.
Rosenberg, I.
Fabry, M.
Rezacova, P.
FEBS JOURNAL, 2009, 276 : 159 - 159
[36] Structure-based drug design of selective 5'-nucleotidases inhibitors
Pachl, Petr
Brynda, Jiri
Rosenberg, Ivan
Fabry, Milan
Rezacova, Pavlina
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2011, 67 : C227 - C228
[37] Structure-based design and optimization of potent inhibitors of the adenoviral protease
Grosche, Philipp
Sirockin, Finton
Mac Sweeney, Aengus
Ramage, Paul
Erbel, Paul
Melkko, Samu
Bernardi, Anna
Hughes, Nicola
Ellis, David
Combrink, Keith D.
Jarousse, Nadine
Altmann, Eva
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (03) : 438 - 443
[38] Structure-based optimization of novel azepane derivatives as PKB inhibitors
Breitenlechner, CB
Wegge, T
Berillon, L
Graul, K
Marzenell, M
Friebe, WG
Thomas, U
Schumacher, R
Huber, R
Engh, RA
Masjost, B
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (06) : 1375 - 1390
[39] DISCOVERY OF A SERIES OF NONPEPTIDIC HIV PROTEASE INHIBITORS VIA STRUCTURE-BASED ITERATIVE DRUG DESIGN
LEWIS, K
MUSICK, L
WU, BW
ANDRADA, D
SHETTY, B
DAVIES, J
REICH, S
APPELT, K
MELNICK, M
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1994, 207 : 20 - MEDI
[40] Structure-Based Drug Design of Novel Aurora Kinase A Inhibitors: Structural Basis for Potency and Specificity
Coumar, Mohane Selvaraj
Leou, Jiun-Shyang
Shukla, Paritosh
Wu, Jian-Sung
Dixit, Ajay Kumar
Lin, Wen-Hsing
Chang, Chun-Yu
Lien, Tzu-Wen
Tan, Uan-Kang
Chen, Chun-Hwa
Hsu, John T-A.
Chao, Yu-Sheng
Wu, Su-Ying
Hsieh, Hsing-Pang
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (04) : 1050 - 1062

← 1 2 3 4 5 →